These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9431027)

  • 1. Novel 1,5-benzodiazepines as CCK-B ligands. Effect of aryl-carbamic substituents at the C-3 position together with halogen substitution on the benzo-fused ring.
    Tranquillini ME; Cassarà PG; Corsi M; Curotto G; Donati D; Finizia G; Pentassuglia G; Polinelli S; Tarzia G; Ursini A; van Amsterdam FT
    Arch Pharm (Weinheim); 1997 Nov; 330(11):353-7. PubMed ID: 9431027
    [No Abstract]   [Full Text] [Related]  

  • 2. 5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor.
    Castro JL; Broughton HB; Russell MG; Rathbone D; Watt AP; Ball RG; Chapman KL; Patel S; Smith AJ; Marshall GR; Matassa VG
    J Med Chem; 1997 Aug; 40(16):2491-501. PubMed ID: 9258356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of 1,5-benzodiazepines with bridged cycloalkyl substituents at the N-1 position as potent and selective CCK-B Ligands.
    Finizia G; Donati D; Pentassuglia G; Polinelli S; Tarzia G; Tranquillini ME; Ursini A
    Arch Pharm (Weinheim); 1998 Jan; 331(1):41-4. PubMed ID: 9507701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Veber DE; Anderson PS; Freidinger RM
    J Med Chem; 1989 Jan; 32(1):13-6. PubMed ID: 2909725
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.
    Ursini A; Capelli AM; Carr RA; Cassarà P; Corsi M; Curcuruto O; Curotto G; Dal Cin M; Davalli S; Donati D; Feriani A; Finch H; Finizia G; Gaviraghi G; Marien M; Pentassuglia G; Polinelli S; Ratti E; Reggiani AM; Tarzia G; Tedesco G; Tranquillini ME; Trist DG; Van Amsterdam FT
    J Med Chem; 2000 Oct; 43(20):3596-613. PubMed ID: 11020274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
    Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
    Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry.
    Hagishita S; Seno K; Kamata S; Haga N; Ishihara Y; Ishikawa M; Shimamura M
    Bioorg Med Chem; 1997 Jul; 5(7):1433-46. PubMed ID: 9377103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial solid phase synthesis of multiply substituted 1,4-benzodiazepines and affinity studies on the CCK2 receptor (part 1).
    Lattmann E; Billington DC; Poyner DR; Arayarat P; Howitt SB; Lawrence S; Offel M
    Drug Des Discov; 2002; 18(1):9-21. PubMed ID: 12375632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
    Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
    J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists.
    Evans BE; Rittle KE; Bock MG; DiPardo RM; Freidinger RM; Whitter WL; Gould NP; Lundell GF; Homnick CF; Veber DF
    J Med Chem; 1987 Jul; 30(7):1229-39. PubMed ID: 2885419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities.
    Tabuchi S; Nakanishi I; Satoh Y
    Bioorg Med Chem Lett; 1998 Jun; 8(12):1449-54. PubMed ID: 9873368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Veber DF; Freidinger RM; Chang RS; Chen TB; Lotti VJ
    J Med Chem; 1990 Jan; 33(1):450-5. PubMed ID: 2153212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diastereomeric separation of 1,5-benzodiazepines due to the presence of a chiral centre on the N-5 alkylic chain.
    Araldi GL; Donati D; Tranquillini ME; Ursini A
    Farmaco; 1998 Jan; 53(1):49-54. PubMed ID: 9543726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of N1-substituted-3-propyl-1,4-benzodiazepine-2-ones as cholecystokinin (CCK2) receptor ligands.
    Lattmann E; Sattayasai J; Billington DC; Poyner DR; Puapairoj P; Tiamkao S; Airarat W; Singh H; Offel M
    J Pharm Pharmacol; 2002 Jun; 54(6):827-34. PubMed ID: 12078999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Veber DF; Freidinger RM; Chang RS; Lotti VJ
    J Med Chem; 1988 Jan; 31(1):176-81. PubMed ID: 3336017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
    Evans BE; Rittle KE; Bock MG; DiPardo RM; Freidinger RM; Whitter WL; Lundell GF; Veber DF; Anderson PS; Chang RS
    J Med Chem; 1988 Dec; 31(12):2235-46. PubMed ID: 2848124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological activity of analogues of YM022. Novel (3-amino substituted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antagonists.
    Satoh M; Okamoto Y; Koshio H; Ohta M; Nishida A; Akuzawa S; Miyata K; Mase T; Semple G
    Chem Pharm Bull (Tokyo); 1996 Jul; 44(7):1412-4. PubMed ID: 8706146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Freidinger RM; Chang RS; Lotti VJ
    J Med Chem; 1988 Jan; 31(1):264-8. PubMed ID: 3336026
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
    J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative structure-activity relationship study on some nonpeptidal cholecystokinin antagonists.
    Sinha J; Kurup A; Paleti A; Gupta SP
    Bioorg Med Chem; 1999 Jun; 7(6):1127-30. PubMed ID: 10428383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.